Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
5.18
-0.27 (-4.95%)
Oct 10, 2025, 3:16 PM EDT - Market open
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $719.00K in the quarter ending June 30, 2025, with 163.37% growth. This brings the company's revenue in the last twelve months to $2.31M, up 510.85% year-over-year. In the year 2024, Atai Life Sciences had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$2.31M
Revenue Growth
+510.85%
P/S Ratio
505.91
Revenue / Employee
$42,759
Employees
54
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
| Dec 31, 2021 | 20.38M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ATAI News
- 9 days ago - Atai Life Sciences: Still A Decent Prospect - But Only Just - Seeking Alpha
- 17 days ago - Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients - Benzinga
- 17 days ago - atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression - GlobeNewsWire
- 4 weeks ago - Atai Life Sciences N.V. (ATAI) Presents at H.C. - Seeking Alpha
- 6 weeks ago - atai Life Sciences to Participate in September Investor Conferences - GlobeNewsWire
- 2 months ago - Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus - Seeking Alpha
- 2 months ago - Why Is ATAI Life Sciences Stock Trading Lower On Monday? - Benzinga
- 2 months ago - ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga